Skip to content

Study · Observational study · n = 215 · 2019

5 results

Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.

Lyu H, Zhao SS, Yoshida K, Tedeschi SK, Xu C, Nigwekar SU, Leder BZ, Solomon DH

The Journal of clinical endocrinology and metabolism1 Nov 2019Cited by 29 (Europe PMC)

PMID31265071 (opens in a new tab)PMCIDPMC6785688 (opens in a new tab)DOI10.1210/jc.2019-00924 (opens in a new tab)PepBankPUB-31265071
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients switching from long-term bisphosphonates, teriparatide use was linked to higher annualized spine BMD change than denosumab.

    In plain wordsIn patients switching from bisphosphonates, teriparatide use was linked to greater spine bone density gains than denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseAnnualized spine BMD change
    Study

    n = 215

    Comparator
    Denosumab
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Annualized BMD difference
    1.3%
    spine versus denosumab

    Source sentences

    Summary
    Compared with denosumab users, teriparatide users had higher annualized BMD change at the spine by 1.3% (95% CI 0.02, 2.7%) but lower at the total hip by -2.2% (95% CI -2.9 to -1.5%) and the femoral neck by -1.1% (95% CI -2.1 to -0.1%).
    2 context sentences
    Summary · context
    Observational cohort study using electronic medical records from two academic medical centers in the United States.
    Summary · context
    The study population included osteoporotic patients >45 years who received bisphosphonates >1 year before switching to teriparatide or denosumab.
  2. 02HumanObservational studyEfficacy outcome

    In patients switching from long-term bisphosphonates, teriparatide use was linked to lower annualized total hip BMD change than denosumab.

    In plain wordsIn patients switching from bisphosphonates, teriparatide use was linked to lower hip bone density change than denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseAnnualized total hip BMD change
    Study

    n = 215

    Comparator
    Denosumab
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Annualized BMD difference
    −2.2%
    total hip versus denosumab

    Source sentences

    Summary
    Compared with denosumab users, teriparatide users had higher annualized BMD change at the spine by 1.3% (95% CI 0.02, 2.7%) but lower at the total hip by -2.2% (95% CI -2.9 to -1.5%) and the femoral neck by -1.1% (95% CI -2.1 to -0.1%).
    2 context sentences
    Summary · context
    Observational cohort study using electronic medical records from two academic medical centers in the United States.
    Summary · context
    The study population included osteoporotic patients >45 years who received bisphosphonates >1 year before switching to teriparatide or denosumab.
  3. 03HumanObservational studyEfficacy outcome

    In patients switching from long-term bisphosphonates, teriparatide use was linked to lower annualized femoral neck BMD change than denosumab.

    In plain wordsIn patients switching from bisphosphonates, teriparatide use was linked to lower femoral neck bone density change than denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseAnnualized femoral neck BMD change
    Study

    n = 215

    Comparator
    Denosumab
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Annualized BMD difference
    −1.1%
    femoral neck versus denosumab

    Source sentences

    Summary
    Compared with denosumab users, teriparatide users had higher annualized BMD change at the spine by 1.3% (95% CI 0.02, 2.7%) but lower at the total hip by -2.2% (95% CI -2.9 to -1.5%) and the femoral neck by -1.1% (95% CI -2.1 to -0.1%).
    2 context sentences
    Summary · context
    Observational cohort study using electronic medical records from two academic medical centers in the United States.
    Summary · context
    The study population included osteoporotic patients >45 years who received bisphosphonates >1 year before switching to teriparatide or denosumab.
  4. 04HumanObservational studyEfficacy outcome

    In patients switching from long-term bisphosphonates, teriparatide use was linked to transient hip BMD loss during the first year.

    In plain wordsIn patients switching from bisphosphonates, teriparatide use was linked to temporary hip bone density loss during the first year.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseHip BMD during first year
    Study

    n = 110

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Those who switched to teriparatide had a transient loss of hip BMD for the first year, with no overall increase in the total hip BMD over 2 years.
    2 context sentences
    Summary · context
    Observational cohort study using electronic medical records from two academic medical centers in the United States.
    Summary · context
    The study population included osteoporotic patients >45 years who received bisphosphonates >1 year before switching to teriparatide or denosumab.
  5. 05HumanObservational studyEfficacy outcome

    In patients switching from long-term bisphosphonates, teriparatide use was linked to no overall total hip BMD increase over 2 years.

    In plain wordsIn patients switching from bisphosphonates, teriparatide use was linked to no overall hip bone density increase over 2 years.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTotal hip BMD over two years
    Study

    n = 110

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Those who switched to teriparatide had a transient loss of hip BMD for the first year, with no overall increase in the total hip BMD over 2 years.
    2 context sentences
    Summary · context
    Observational cohort study using electronic medical records from two academic medical centers in the United States.
    Summary · context
    The study population included osteoporotic patients >45 years who received bisphosphonates >1 year before switching to teriparatide or denosumab.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.